Loading
Systemic Sclerosis and Related Diseases / Voice and Speech Disorders · Journal article
Frontiers in Immunology · July 10, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review synthesizing current understanding of depression and anxiety in systemic sclerosis, proposing that immune dysregulation, cerebral microvascular damage, and HPA axis dysregulation underlie psychiatric comorbidity. The review calls for integrated rheumatology-psychiatry care and specific biologics (IL-6/JAK inhibitors) and neuromodulation (tVNS), but presents no new empirical evidence or trial data to support these recommendations.
Narrative review. Patients with systemic sclerosis meeting diagnostic criteria for depression or anxiety..
Prevalence of clinically significant depression or anxiety disorders in SSc ranges from 30%–50% among patients meeting diagnostic criteria. Risk factors include multi-organ involvement (lung fibrosis, digital ulcers), chronic pain, physical disability, and disease-related stigma. Proposed pathophysiological mechanisms: immune dysregulation and neuroinflammation via pro-inflammatory cytokines (IL-6, TNF-α), pathogenic autoantibodies, and gut-brain axis disruption.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review suggests that clinicians managing SSc should integrate psychiatric assessment and consider rheumatology-psychiatry collaboration, immune-targeted biologics, and vagal neuromodulation alongside conventional psychiatric care. However, the mechanistic proposals and therapeutic recommendations lack primary trial evidence and should be treated as emerging concepts requiring clinical validation.
This is a narrative review proposing mechanistic pathways and therapeutic approaches for neuropsychiatric comorbidity in systemic sclerosis, without new empirical data or clinical trials to test these hypotheses.
As stated by the source record.
Quoted from the source exactly as published.
This review suggests that clinicians managing SSc should integrate psychiatric assessment and consider rheumatology-psychiatry collaboration, immune-targeted biologics, and vagal neuromodulation alongside conventional psychiatric care. However, the mechanistic proposals and therapeutic recommendations lack primary trial evidence and should be treated as emerging concepts requiring clinical validation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This review addresses the high prevalence of depression and anxiety in systemic sclerosis (SSc), as well as the core biological, psychological and social mechanisms underlying such psychiatric comorbidities, The prevalence of clinically significant depression or anxiety disorders reaches 30%-50% among patients with SSc who satisfy corresponding diagnostic criteria. Established risk factors encompass multi-organ involvement (e.g., lung fibrosis, digital ulcers), chronic pain, physical disability and disease-related stigma. Three key pathophysiological mechanisms drive this comorbidity: immune dysregulation induces neuroinflammation via pro-inflammatory cytokines (IL-6, TNF-α), pathogenic autoantibodies and gut-brain axis disruption; cerebral microvascular damage and chronic hypoxia impair emotion-regulating neural circuits; tissue fibrosis and persistent stress over activate the HPA axis, forming a pathogenic cycle connecting systemic inflammation, glucocorticoid resistance and negative mood. Clinical management of SSc should extend beyond conventional antidepressants and cognitive behavioral therapy to include integrated rheumatology-psychiatry care, IL-6/JAK-targeted biologics and transcutaneous vagus nerve stimulation (tVNS), all designed to ameliorate patients' physical and psychiatric symptoms simultaneously. In conclusion, psychiatric comorbidity in SSc stems from the intricate interplay of biological, psychological and social factors. Elucidating these mechanisms facilitates the development of targeted therapeutic strategies that address both systemic SSc manifestations and associated mental health conditions, thereby enhancing patients' health-related quality of life and long-term psychiatric outcomes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.